Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative.

Figure 7 illustrates that the concentrations of cTnI at 12, 24, and 48 h post-IV-dosing of DoxQ were lower than after Dox dosing, though this did not reach statistical significance and thus the cardiac toxicity induced by DoxQ and Dox was not different using this biomarker.

also in 111,027 other papers